Approval extremely likely with such postive response on FDA meeting. Oncologists not switching to the safer more effective form will be taking on enormous malpractice risk-especially if heart failure occurs. Transition will be rapid- much better choice for patients- an defensive medicine for themselves.
News 
Market Data 
Discover 
